B
Bull
Bull · 25%NNVC
$1.95
Precio del escenario
$1.240
-0.039 (-3.13%)Al cierre
Loading chart…
- High
- 1.276
- Open
- 1.260
- VWAP
- 1.25
- Vol
- 189.22K
- Mkt Cap
- 20.44M
- Low
- 1.220
- Amount
- 235.65K
- EV/EBITDA, TTM
- 0.00
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
AI analysis of NanoViricides, Inc (NNVC)
holdCurrently, NanoViricides Inc is not a strong buy due to its low current price of $1.24 and a very low RSI of 20.684, indicating it is oversold. However, the potential upside is significant with an analyst price target of $6, suggesting a possible 384% increase. The main risk is its ongoing losses, with a net income of -2220719.00 USD in Q2 2026, which raises concerns about its financial health.
Métricas de valoración
The current forward P/E ratio for NanoViricides, Inc (NNVC) is 0.00, compared to its 5-year average forward P/E of -2.61.
Alphio AI Price Scenarios for NNVC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
8.507-24seekingalphaNanoViricides Enters Securities Purchase Agreement for Direct Offering
9.007-06stocktwitsNanoViricides Receives Approval for Phase II Trial in DRC
8.506-29NewsfilterNanoViricides Receives Rare Pediatric Disease Drug Designation
8.506-05Yahoo FinanceNanoViricides Files Preliminary Prospectus with SEC
8.505-28NASDAQ.COMQ32 Bio Soars Over 85% on $55 Million Private Placement Announcement
NNVC FAQ — answered by Alphio AI
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Currently, NanoViricides Inc is not a strong buy due to its low current price of $1.24 and a very low RSI of 20.684, indicating it is oversold. However, the potential upside is significant with an analyst price target of $6, suggesting a possible 384% increase. The main risk is its ongoing losses, with a net income of -2220719.00 USD in Q2 2026, which raises concerns about its financial health.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.